ImpediMed enters into agreement with Mayo Clinic

Company News

by Jessica Ellerm

ImpediMed Limited (ASX:IPD) has announced it has entered into a 5 year master clinical trial agreement with the Mayo Clinic.
The trial will explore additional indications for its fluid status and body composition monitoring technology.
Clinical trials will be conducted at multiple U.S. locations and will also explore if the ImpediMed technology has wider applications in cardiology, nephrology, wellness and fitness.
Interim results from the trials are expected to be released late 2016.
ImpediMed Limited reported a net loss of $11.2 million at 31 December 2015.

Jessica Ellerm

Finance News Network
Jessica joined FNN in April 2016 and presents the Australian Share Market Outlook, and reports on the morning's leading business stories. Alongside FNN Jessica is a fintech industry commentator, writing for her own blog and a number of international online publications.